{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T21:55:25Z","timestamp":1715723725041},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Crohn's and Colitis"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.crohns.2009.02.005","type":"journal-article","created":{"date-parts":[[2009,3,26]],"date-time":"2009-03-26T13:10:31Z","timestamp":1238073031000},"page":"168-174","source":"Crossref","is-referenced-by-count":9,"title":["An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis based on results from randomised controlled trial"],"prefix":"10.1093","volume":"3","author":[{"given":"Mark P.","family":"Connolly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandy K.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig J.","family":"Currie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Marteau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris S.J.","family":"Probert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon P.L.","family":"Travis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"10.1016\/j.crohns.2009.02.005_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0016-5085(94)90054-X","article-title":"Course of ulcerative colitis: analysis of changes in disease activity over years","volume":"107","author":"Langholz","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.02.005_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.crohns.2007.11.001","article-title":"European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis","volume":"2","author":"Stange","year":"2008","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.crohns.2009.02.005_bib3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/MEG.0b013e3282f16a62","article-title":"Ulcerative colitis and irritable bowel syndrome: relationships with quality of life","volume":"20","author":"Ansari","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2009.02.005_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.crohns.2007.06.005","article-title":"Impact of inflammatory bowel disease impact on quality of life: results of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) patient survey","volume":"1","author":"Ghosh","year":"2007","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.crohns.2009.02.005_bib5","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1136\/gut.2004.041616","article-title":"Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study","volume":"53","author":"Bassi","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2009.02.005_bib6","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1111\/j.1572-0241.2001.03946.x","article-title":"The relationship between inflammatory bowel disease and socioeconomic variables","volume":"96","author":"Bernstein","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.02.005_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1572-0241.2008.02130.x","article-title":"Cost-effectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitis","volume":"103","author":"Yen","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2009.02.005_bib8","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1053\/j.gastro.2006.05.052","article-title":"Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation","volume":"131","author":"Odes","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.02.005_bib9","doi-asserted-by":"crossref","first-page":"352","DOI":"10.18553\/jmcp.2008.14.4.352","article-title":"Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients","volume":"14","author":"Bickston","year":"2008","journal-title":"J Manag Care Pharm"},{"issue":"7 Suppl A","key":"10.1016\/j.crohns.2009.02.005_bib10","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.18553\/jmcp.2007.13.s7-a.2","article-title":"Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costs","volume":"13","author":"Tindall","year":"2007","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.crohns.2009.02.005_bib11","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/gut.2004.060103","article-title":"Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild\/moderate active ulcerative colitis: a randomized, double blind, placebo controlled study","volume":"54","author":"Marteau","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2009.02.005_bib12","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.gastro.2006.12.038","article-title":"A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis","volume":"132","author":"D\u2019Haens","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2009.02.005_bib13","first-page":"17","article-title":"Remission in trials of ulcerative colitis \u2014 what does it mean?","volume":"30","author":"Travis","year":"2006","journal-title":"Practical Gastroenterol"},{"key":"10.1016\/j.crohns.2009.02.005_bib14","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1007\/s10198-003-0182-5","article-title":"A single European currency for EQ-5D health states. Results from a six-country study","volume":"4","author":"Greiner","year":"2003","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.crohns.2009.02.005_bib15","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/hec.1148","article-title":"A taxonomy of model structures for economic evaluation of health technologies","volume":"15","author":"Brennan","year":"2007","journal-title":"Health Econ"},{"key":"10.1016\/j.crohns.2009.02.005_bib16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.crohns.2007.11.002","article-title":"European evidence-based consensus on the management of ulcerative colitis: current management","volume":"2","author":"Travis","year":"2008","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.crohns.2009.02.005_bib17","series-title":"NICE guidance TA140","article-title":"Infliximab for subacute manifestations of ulcerative colitis","author":"NICE","year":"2008"},{"key":"10.1016\/j.crohns.2009.02.005_bib18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/gut.1.3.217","article-title":"An assessment of prednisone, salazopyrin and topical hydrocortisone hemisuccinate used as outpatient treatment for ulcerative colitis","volume":"1","author":"Lennard-Jones","year":"1960","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2009.02.005_bib19","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"issue":"Suppl II","key":"10.1016\/j.crohns.2009.02.005_bib20","first-page":"A260","article-title":"Health related utility among adults with remitting ulcerative colitis maintained with oral mesalazine over the long term: findings from the PODIUM study","author":"Poole","year":"2008","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.crohns.2009.02.005_bib21","doi-asserted-by":"crossref","DOI":"10.1097\/00042737-200211000-00008","article-title":"Validation of the EuroQol questionnaire in patients with inflammatory bowel disease","volume":"14","author":"Konig","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2009.02.005_bib22","series-title":"Guidelines for the management of inflammatory bowel disease in adults","first-page":"v1","article-title":"On behalf of the IBD Section of the British Society ofGastroenterology","volume":"53 Suppl V","author":"Carter","year":"2004"},{"key":"10.1016\/j.crohns.2009.02.005_bib23","series-title":"Unit costs of health and social care","author":"Curtis","year":"2007"},{"issue":"5","key":"10.1016\/j.crohns.2009.02.005_bib24","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/00019053-200017050-00006","article-title":"Handling uncertainty in cost-effectiveness models","volume":"17","author":"Briggs","year":"2000","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.crohns.2009.02.005_bib25","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/hec.985","article-title":"Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra","volume":"14","author":"Claxton","year":"2005","journal-title":"Health Econ"},{"key":"10.1016\/j.crohns.2009.02.005_bib26","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1177\/0272989X9801800209","article-title":"Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis","volume":"18","author":"Stinnett","year":"1998","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.crohns.2009.02.005_bib27","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/bmj.329.7459.224","article-title":"National Institute for Clinical Excellence and its value judgments","volume":"329","author":"Rawlins","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.crohns.2009.02.005_bib28","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/hec.864","article-title":"Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis","volume":"13","author":"Devlin","year":"2004","journal-title":"Health Econ"},{"key":"10.1016\/j.crohns.2009.02.005_bib29","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.cgh.2006.05.003","article-title":"Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis?","volume":"4","author":"Arseneau","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2009.02.005_bib30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1524-4733.2003.00234.x","article-title":"Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices\u2014modeling studies","volume":"6","author":"Weinstein","year":"2003","journal-title":"Value in Health"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994609000142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994609000142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/3\/3\/168\/7799342\/3-3-168.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,3]],"date-time":"2021-10-03T16:38:50Z","timestamp":1633279130000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-lookup\/doi\/10.1016\/j.crohns.2009.02.005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S1873994609000142"],"URL":"https:\/\/doi.org\/10.1016\/j.crohns.2009.02.005","relation":{},"ISSN":["1873-9946"],"issn-type":[{"value":"1873-9946","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}